TLR9 and telomere syndrome: In this study, we found that the combination of CpG (unmethylated cytosine-phosphorothioate-guanosine forms of DNA), a TLR9 agonist, and RT suppresses tumor growth significantly using autochthonous mouse models of STS in which the tumor gradually develops under surveillance by an intact immune system (10, 11).